- Home
- REVB vs ONCO Comparison
REVB vs ONCO Comparison
Compare REVB & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- ONCO
- Stock Information
- Founded
- REVB 2020
- ONCO 2018
- Country
- REVB United States
- ONCO United States
- Employees
- REVB N/A
- ONCO N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- ONCO Health Care
- Exchange
- REVB Nasdaq
- ONCO Nasdaq
- Market Cap
- REVB 5.4M
- ONCO 4.6M
- IPO Year
- REVB N/A
- ONCO 2022
- Fundamental
- Price
- REVB $0.40
- ONCO $0.53
- Analyst Decision
- REVB
- ONCO
- Analyst Count
- REVB 0
- ONCO 0
- Target Price
- REVB N/A
- ONCO N/A
- AVG Volume (30 Days)
- REVB 6.8M
- ONCO 17.2M
- Earning Date
- REVB 11-08-2024
- ONCO 12-10-2024
- Dividend Yield
- REVB N/A
- ONCO N/A
- EPS Growth
- REVB N/A
- ONCO N/A
- EPS
- REVB N/A
- ONCO N/A
- Revenue
- REVB N/A
- ONCO $1,870,605.00
- Revenue This Year
- REVB N/A
- ONCO N/A
- Revenue Next Year
- REVB N/A
- ONCO N/A
- P/E Ratio
- REVB N/A
- ONCO N/A
- Revenue Growth
- REVB N/A
- ONCO N/A
- 52 Week Low
- REVB $0.28
- ONCO $0.32
- 52 Week High
- REVB $25.26
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- REVB 39.87
- ONCO 41.58
- Support Level
- REVB $0.39
- ONCO $0.46
- Resistance Level
- REVB $0.53
- ONCO $0.76
- Average True Range (ATR)
- REVB 0.13
- ONCO 0.23
- MACD
- REVB 0.00
- ONCO 0.05
- Stochastic Oscillator
- REVB 7.54
- ONCO 9.97
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.